1-[3-(三氟甲基)苯基]环丙烷甲腈 | 124305-68-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-[3-(三氟甲基)苯基]环丙烷甲腈
• 英文名称: 1-(3-(trifluoromethyl)phenyl)cyclopropane-1-carbonitrile
• 英文别名: 1-[3-(trifluoromethyl)phenyl]cyclopropanecarbonitrile；1-(3-(Trifluoromethyl)phenyl)cyclopropanecarbonitrile；1-[3-(trifluoromethyl)phenyl]cyclopropane-1-carbonitrile
• CAS: 124305-68-6
• 化学式: C₁₁H₈F₃N
• mdl: MFCD07374416
• 分子量: 211.186
• InChiKey: CRIZCGCPHXFSCH-UHFFFAOYSA-N

物化性质

• 沸点：
  254.6±40.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-[3-(三氟甲基)苯基]环丙烷甲腈 在 lithium hydroxide 作用下， 以 水 为溶剂， 生成 1-[3-(三氟甲基)苯基]环丙烷羧酸
  参考文献：
  名称：

  铑催化环丙基CH键的对映选择性硅烷化

  摘要：

  氢硅烷基醚是通过环丙基甲醇与二乙基硅烷的脱氢硅烷化原位生成的，在源自铑前体和双膦的铑催化剂存在下，以高收率和高对映体过量进行环丙基CH键的不对称分子内硅烷化（ S )-DTBM-SEGPHOS。所得的对映体富集的氧杂硅氧烷是 Tamao-Fleming 氧化形成环丙醇的合适底物，同时保留了 C−H 甲硅烷基化的ee值。初步的机制数据表明，C−H 裂解可能是转换限制和对映选择性决定步骤。

  DOI：

  10.1002/anie.201603153
• 作为产物：
  描述：

  1-溴-2-氯乙烷 、 间三氟甲基苯乙腈 在 苄基三乙基溴化铵 、 sodium hydroxide 作用下， 以 水 、 甲苯 为溶剂， 反应 96.0h， 以72%的产率得到1-[3-(三氟甲基)苯基]环丙烷甲腈
  参考文献：
  名称：

  通过MgI 2介导的芳基环丙基腈扩环，非对映选择性合成2,3-二芳基-3-氰基取代的吡咯烷

  摘要：

  已经证明了MgI 2介导的芳基取代的环丙基腈与甲苯磺酰基亚胺的反应，得到2，3-二芳基-3-氰基取代的吡咯烷。在所有情况下，反式非对映异构体被确定为主要产物。反应的总收率和非对映选择性显示出对芳基环丙基腈和甲苯磺酰基亚胺的电子和空间要求的敏感性。就产率和非对映选择性而言，在两个反应伙伴上均用吸电子取代基取代被证明是有益的。

  DOI：

  10.1016/j.tetlet.2020.152325

文献信息

• Methods and Compositions for Selectin Inhibition
  申请人：Kaila Neelu

  公开号：US20080255192A1

  公开（公告）日：2008-10-16

  The present teachings relate to novel compounds of formula I: wherein the constituent variables are as defined herein. Compounds of the present teachings can act as antagonists of the mammalian adhesion proteins known as selecting. Methods for treating or preventing selectin-mediated disorders are provided, which include administration of these compounds in a therapeutically effective amount.

  本教学涉及到式I的新化合物： 其中组成变量如本文所定义。本教学的化合物可以作为被称为选择素的哺乳动物粘附蛋白的拮抗剂。提供了治疗或预防选择素介导的疾病的方法，包括以治疗有效剂量给予这些化合物。
• THIAZOLE DERIVATIVE
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2530078A1

  公开（公告）日：2012-12-05

  Provided is a compound having an agonist action on GPR52, which is useful as a prophylactic or therapeutic drug for mental diseases such as schizophrenia and the like, and the like. A compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  提供了一种对GPR52具有激动剂作用的化合物，该化合物可作为预防或治疗精神疾病如精神分裂症等的药物。一种由以下通式（I）表示的化合物：其中各个符号的定义如说明书中所述，或其盐形式。
• COMPOUNDS FOR TREATING AND PREVENTING GROWTH HORMONE RECEPTOR-DEPENDENT CONDITIONS
  申请人：UMC Utrecht Holding B.V.

  公开号：EP3811945A1

  公开（公告）日：2021-04-28

  The invention relates to compounds, in particular pyrimidine-2,4-diamines, analogues and salts thereof and pharmaceutical compositions comprising pyrimidine-2,4-diamines analogues and salts thereof for use in the treatment and prevention of a disease, in particular a growth hormone receptor-dependent condition. The invention also relates to methods of using these compounds and compositions to treat physiological dsorders related to the amount or activity of growth hormone. In a particular embodiment, the invention relates to a compound according to formula 1 for use in the treatment or prevention of a disease in a subject

  这项发明涉及化合物，特别是嘧啶-2,4-二胺，其类似物和盐以及包含嘧啶-2,4-二胺类似物和盐的药物组合物，用于治疗和预防疾病，特别是生长激素受体依赖性疾病。该发明还涉及使用这些化合物和组合物治疗与生长激素量或活性相关的生理紊乱的方法。在一个特定实施例中，该发明涉及根据式1的化合物用于治疗或预防受试者的疾病。
• Substituted-aryl cyclopropanecarbonitriles and derivatives thereof as
  申请人：Monsanto Company

  公开号：US04859232A1

  公开（公告）日：1989-08-22

  Substituted-aryl cyclopropanecarbonitriles and derivative compounds are antidotes for thiocarbamate, triazine-type and acetamide herbicides. These antidote compounds are especially effective in safening thiocarbamate herbicides used to control grassy weeds in wheat.

  取代芳基环丙烷腈及其衍生物是对硫代氨基甲酸酯、三嗪类和乙酰胺类除草剂的解毒剂。这些解毒剂化合物在安全化控制小麦中的草本杂草所使用的硫代氨基甲酸酯除草剂中尤其有效。
• Discovery of 2-[1-(4-Chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic Acid (PSI-421), a P-Selectin Inhibitor with Improved Pharmacokinetic Properties and Oral Efficacy in Models of Vascular Injury
  作者：Adrian Huang、Alessandro Moretto、Kristin Janz、Michael Lowe、Patricia W. Bedard、Steve Tam、Li Di、Valerie Clerin、Natalia Sushkova、Boris Tchernychev、Desiree H. H. Tsao、James C. Keith、Gray D. Shaw、Robert G. Schaub、Qin Wang、Neelu Kaila

  DOI：10.1021/jm9013696

  日期：2010.8.26

  Previously, we reported the discovery of PSI-697 (1a), a C-2 benzyl substituted quinoline salicylic acid-based P-selectin inhibitor. It is active in a variety of animal models of cardiovascular disease. Compound 1a has also been shown to be well tolerated and safe in healthy volunteers at doses of up to 1200 mg in a phase 1 single ascending dose study. However, its oral bioavailability was low. Our goal was to identify a back up compound with equal potency, increased solubility, and increased exposure. We expanded our structure activity-studies in this series by branching at the alpha position of the C-2 benzyl side chain and through modification of substituents on the carboxylic A-ring of the quinoline. This resulted in discovery of PSI-421 with marked improvement in aqueous solubility and pharmacokinetic properties. This compound has shown oral efficacy in animal models of arterial and venous injury and was selected as a preclinical development compound for potential treatment of such diseases as atherosclerosis and deep vein thrombosis.